Compare Ginkgo Bioworks Holdings Inc (DNA) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Trade Desk Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.87 (market cap $772.39M), while Trade Desk Inc trades at $12.38 (market cap $5.72B). The key difference: Trade Desk Inc is far larger — about 7.4× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Trade Desk Inc for 72 Days on average.
| DNA | TTD | |
|---|---|---|
Market Cap | $772.39M | $5.72B |
Volume | 6,453,273 | 14,380,236 |
Sector | Health | Media |
52-Week High | $15.83 | $54.13 |
52-Week Low | $5.48 | $11.92 |
Typical Hold Time | 7 Days | 72 Days |
Enterprise Value | $874.34M | $4.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
TTD trades at $12.09, up 1.43% on the day but remains under pressure with a bearish technical signal. Revenue grew to $2.90B in 2025, though net income margin slipped to 15.3%. Recent earnings show volatility, with a Q2 beat but Q1 miss. The stock faces stiff competition and slowing growth, reflected in negative cash flow trends and a workforce reduction announced in September 2026.
The outlook is cautious; while valuation ratios appear low, competitive threats from tech giants and declining growth pose significant risks. Analyst consensus is mixed with a $14.72 price target, but the stock's 68% YTD drop underscores investor skepticism. Upside depends on execution in connected TV and new verticals like healthcare ads.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
